Psychedelic Use During Pandemic Linked to Mental Health Improvements

Recent research from a British long-term study involving over 240,000 participants reveals noteworthy improvements in mental health among individuals using psychedelics alongside cannabis during the COVID-19 pandemic. Published in the *Journal of Psychopharmacology*, the study, led by Maria Bălăeţ at King’s College London, indicates that those who combined these substances transitioned from poorer mental health to levels similar to non-drug users.

In contrast, other drug user groups displayed deteriorating anxiety and depression symptoms, highlighting the unique benefits observed in cannabis and psychedelic users. The research utilized data spanning from 2019 to 2022, tracked via *The Great British Intelligence Test*, using metrics like the PHQ-9 and GAD-7 scales for mental health assessment. Participants were categorized into six groups, which included those who used cannabis only, cocaine, or a combination with psychedelics. Notably, while all drug users were initially shown to have poorer mental health than non-users, the specific group of cannabis and psychedelic users saw significant improvement over time.

However, the observational study design raises questions about causation, leaving it unclear if improved mental health led to increased psychedelic usage or vice versa. Researchers suggest that contextual factors and personal development may play a crucial role in these positive outcomes, emphasizing the need for further research into the nuances of timing, use methods, and psychological recovery linked to psychedelic use.